Metals Focus published its annual Precious Metals Investment Focus report on Saturday (October 25). The report from the leading gold analysis firm outlines the investment options available for those interested in leveraging rising demand for precious metals such as gold and silver. It also highlights key supply and demand trends shaping the precious metals market and driving prices now and over the next 12 months. Gold surged over 65 percent from the start of 2025 to its record high of US$4,379.13 per ounce on October 17. Not to be outdone, silver skyrocketed more than 88 percent its highest-ever price of US$54.47 per ounce on the same day. Although prices for both precious metals have since pulled back on profit taking, Metals Focus believes the conditions that created these record-high prices are still very much in play. US trade policy driving gold price in 2025 Metals Focus analysts attribute gold’s stellar…

Tight export controls out of the Democratic Republic of Congo (DRC) added tailwinds to cobalt prices in Q3, prompting market watchers to anticipate a shift from oversupply to balance in the coming months. After starting the year at lows unseen since 2016 (US$21,502 per metric ton), cobalt began to rebound in Q2. Prices for the metal then flatlined in the US$33,300 to US$37,000 range from the end of March through September, but a sharp rally in late October sent values to US$47,110, a level last reached in January 2023. Cobalt price, October 25, 2024, to October 23, 2025. Chart via Trading Economics. Much of the cobalt story this year has been dominated by the February export suspension out of the DRC, which supplies roughly three-quarters of the world’s cobalt. The initial curtailment was expected to last four months in an effort to rein in oversupply and stem a price plunge…

Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (the ‘Company’ or ‘Questcorp’) announces that it has closed the first tranche of its non-brokered private placement (the ‘Offering’). In connection with closing, the Company has issued 14,000,334 units (each, a ‘Unit’) at a price of $0.15 per Unit for gross proceeds of $2,100,050. Each Unit consists of one common share of the Company (each, a ‘Share’) and one-half-of-one share purchase warrant (each whole warrant, an ‘Warrant’). Each Warrant entitles the holder to acquire an additional common share of the Company at a price of $0.20 until October 24, 2027, subject to accelerated expiry in the event the closing price of the Shares is $0.50 or higher for ten consecutive trading days. The Company expects to utilize the proceeds of the Offering for advancement of ongoing exploration and drill work at the La Union Gold and Silver Project, upcoming exploration work…

Ed Steer of Ed Steer’s Gold and Silver Digest shares his thoughts on silver’s run past US$50 per ounce, saying that in his view the bull market is just getting started. ‘One way or another we’re going to run into a supply/demand brick wall, and when that day happens we could see triple-digit silver prices in a very, very short period of time,’ he said. Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article. This post appeared first on investingnews.com

The gold price declined from its recent all-time highs this week, sinking to nearly US$4,000 per ounce and recording its biggest one-day decline in more than 12 years. Silver took a similar hit, slipping back below the US$50 per ounce level. The drops have been attributed to factors like a stronger US dollar and lower US-China tensions, as well as profit taking, potentially from traders who are new to the market. Many experts have been anticipating a correction for the metals — their latest rise has been quick, and no asset can go straight up forever. However, there’s also a broad consensus that gold has entered a new phase. For example, Patrick Tuohy of Goldstrom believes gold won’t fall below US$3,000 again. Here’s what Tuohy said: ‘Is this a short-term phenomenon that’s going to have some some dynamics that are going to turn it on its head and it reverses…

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies. Read on to learn what’s been driving these Canadian biotech firms. 1. Eupraxia Pharmaceuticals (TSX:EPRX) Year-on-year gain: 141.23 percentMarket cap: C$410.85 millionShare price: C$8.25 Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues. The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well. Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts. In July, Eupraxia dosed its first patient after advancing…

Astral Resources (AAR:AU) has announced Feysville Land Use Agreement Signed With Marlinyu Ghoorlie Download the PDF here. This post appeared first on investingnews.com